Oncology testing for copy number variants and sequence abnormalities can provide useful information regarding treatment options and prognosis. Our
test offerings include individual and panel testing that can be performed on a variety of tissues. The Affymetrix OncoScan platform allows for
detection of copy number gains and losses, loss of heterozygosity (LOH), enhanced resolution of ~900 cancer genes, and somatic mutations from either
fresh, frozen or parrafin-embedded cancer tissues. Gene sequencing and targeted mutation testing and copy number analysis can serve as a useful
diagnostic and potentially prognostic tool for the analysis of affected tissues or tumors. The detection of copy number variants or specific gene
mutations may enhance treatment decisions.